Listed

IGC Pharma, Inc.: Form 10-Q for the period ended Dec 31, 2016

Filed with the SEC on Feb 21, 2017 and accepted by EDGAR at Feb 21, 2017, 16:09 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2016-12-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2016-10-01 to 2016-12-31$250.0kus-gaap:Revenues
Revenue9 months2016-04-01 to 2016-12-31$487.0kus-gaap:Revenues
Cost of revenue3 months2016-10-01 to 2016-12-31$122.0kus-gaap:CostOfRevenue
Cost of revenue9 months2016-04-01 to 2016-12-31$276.0kus-gaap:CostOfRevenue
Selling, general and administrative3 months2016-10-01 to 2016-12-31$323.0kus-gaap:SellingGeneralAndAdministrativeExpense
Selling, general and administrative9 months2016-04-01 to 2016-12-31$960.0kus-gaap:SellingGeneralAndAdministrativeExpense
Operating income3 months2016-10-01 to 2016-12-31−$386.0kus-gaap:OperatingIncomeLoss
Operating income9 months2016-04-01 to 2016-12-31−$1.3mus-gaap:OperatingIncomeLoss
Interest expense3 months2016-10-01 to 2016-12-31$46.0kus-gaap:InterestExpense
Interest expense9 months2016-04-01 to 2016-12-31$136.0kus-gaap:InterestExpense
Income tax3 months2016-10-01 to 2016-12-31$73.0kus-gaap:IncomeTaxExpenseBenefit
Income tax9 months2016-04-01 to 2016-12-31$1.1mus-gaap:IncomeTaxExpenseBenefit
Net income3 months2016-10-01 to 2016-12-31−$111.0kus-gaap:NetIncomeLoss
Net income9 months2016-04-01 to 2016-12-31−$1.1mus-gaap:NetIncomeLoss
Diluted EPS3 months2016-10-01 to 2016-12-31$0.00us-gaap:EarningsPerShareDiluted
Diluted EPS9 months2016-04-01 to 2016-12-31−$0.04us-gaap:EarningsPerShareDiluted
Basic EPS3 months2016-10-01 to 2016-12-31$0.00us-gaap:EarningsPerShareBasic
Basic EPS9 months2016-04-01 to 2016-12-31−$0.04us-gaap:EarningsPerShareBasic
Diluted shares (weighted)3 months2016-10-01 to 2016-12-3127,446,095 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Diluted shares (weighted)9 months2016-04-01 to 2016-12-3127,446,095 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Operating cash flow9 months2016-04-01 to 2016-12-31−$483.0kus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure9 months2016-04-01 to 2016-12-31$129.0kus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Cash and equivalentsAt period end2016-12-31$744.0kus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2016-12-31$1.8mus-gaap:AssetsCurrent
Total assetsAt period end2016-12-31$11.2mus-gaap:Assets
Current liabilitiesAt period end2016-12-31$761.0kus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2016-12-31$3.6mus-gaap:Liabilities
Long-term debtAt period end2016-12-31$446.0kus-gaap:LongTermDebtNoncurrent
Short-term borrowingsAt period end2016-12-31$0us-gaap:ShortTermBorrowings
Shareholders' equityAt period end2016-12-31$7.5mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001185185-17-000430. Last ingested by Listed: Nov 6, 2026, 16:27 ET. Listed shows no prices and gives no investment advice.